



Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

September 30, 2021

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new preclinical data from several of the company's RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

Details of the upcoming oral presentation at the AACR-NCI-EORTC conference are as follows:

- **Title:** Discovery and Development of RAS(ON) Inhibitors Beyond KRAS^{G12C}
- **Presenter:** Steve Kelsey, M.D., president, research and development
- **Session:** Plenary Session 5: Drugging Difficult Targets
- **Session Date/Time:** Saturday, October 9, 2021, 12:05 – 1:55 p.m. Eastern
- **Session Panel Discussion:** To follow completion of Plenary Session 5 presentations

To access a copy of the presentation slides, please visit the “Events & Presentations” page of Revolution Medicines' website at <https://ir.revmed.com/events-and-presentations>. The presentation slides will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

Additional information on the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutic is available through the conference website at <https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/>

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com